" class="no-js "lang="en-US"> Eagle Genomics Discloses Funding from OMRON Ventures
Tuesday, January 31, 2023

Eagle Genomics Disclose Funding from OMRON Ventures to Drive Sustainability Innovation in Microbiome R&D

Today, Eagle Genomics, the pioneering TechBio platform business applying network science to biology, disclosed additional scale-up funding from Japan-based corporate venture capital firm OMRON Ventures. The funds will support the ongoing development of Eagle Genomics’ e[datascientist]™ platform as well as continued global expansion and increased client impact. The e[datascientist]™ uses multilayer hypergraphs to structure and interrogate data, applying AI to network science to derive data-driven insight journeys into complex problems at scale. The current funding round is ongoing, and open for additional investment opportunities.

Eagle Genomics continues to mature and expand as the leading TechBio company pioneering the application of network science to biological discovery and innovation, across the Food and Nutrition, AgBio, Beauty and Personal Care, and Biopharma industries. The e[datascientist] platform enables enterprise customers to trace digital journeys in data, drive transformative innovations, exploit leading-edge scientific discovery in silico and support differentiated product claims. By networking scientific data to support step-change innovation, Eagle Genomics is bridging the ‘translation gap,’ using scientific knowledge from a range of disparate sources and studies across industries to deliver robust, scientifically underpinned product claims. The company’s partners include household names like Unilever, where research on the skin and oral microbiome, powered by Eagle Genomics’ platform resulted in the development of products and claims relating to the improvement and maintenance of skin and oral health, such as Zendium toothpaste and Dove soap.

As such, Eagle Genomics values supporting its customers’ aspirations as they address ‘One Health’ [4] challenges towards more sustainable and impact-oriented innovation. A knowledge of the microbiome, and host-microbiome interactions across human, animal, and environmental health domains is critical to unlocking radical innovation opportunities that can solve these challenges. This is where the e[datascientist]’s capabilities to efficiently interrogate multi-dimensional microbiome and other biological data plays an invaluable role.

Anthony Finbow, CEO, Eagle Genomics, said: “We are the pre-eminent platform business using next-generation graph technology and network science to drive the Bioeconomy. We support our enterprise customers to achieve more sustainable and impact-orientated innovation outcomes by harnessing the knowledge of the microbiome. This is especially important in areas of unmet clinical need, such as metabolic health and cardiovascular health where the microbiome’s effect is becoming increasingly more prevalent and critical. The current scale-up funding from OMRON Ventures will further our transformational impact across these very important domains and others across One Health”.

Tomoko Inoue, CEO, OMRON VENTURES Co., LTD., said: “In today’s society, which is overflowing with data, OMRON Ventures strives to create new value by leveraging data as an asset. Eagle Genomics and its e[datascientist] platform enables innovation journeys that can yield differentiated products, product claims, and asset repurposing. Its focus on influencing systems-change and data-driven innovation to accelerate the Bioeconomy aligns closely with our principles for social and economic change. We are therefore very pleased to be making our current investment in Eagle Genomics and wish it all the best on its upwards trajectory.”

In October 2022, Eagle Genomics announced a USD $20 million first close of its scale-up funding round. The round was led by abrdn plc, with continued participation from existing investors Environmental Technologies Fund, and a consortium of investors headed by Granpool Innovative Investments.

  1. MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson’s Disease Read more
  2. Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome Read more
  3. Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear Read more
  4. Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors Read more
  5. Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors Read more